November 26, 2003

News Release: Tectin(TM) Development Update

International Wex Technologies Inc. ('Wex'or the 'Company') is pleased to provide an update on its progress with the clinical development of Tectin(TM), the Company's product for the management of pain.
Tectin(TM) for the management of cancer related pain.

Wex is pleased to announce that the Company has had a meeting with Health Canada and, based on that meeting, will be filing for a pivotal Phase IIb/III clinical trial shortly. At the meeting with Health Canada, Wex presented the interim analysis of the Phase IIa trial, along with a Phase IIb/III protocol outline. The Phase IIb/III protocol which will be filed includes input from Health Canada and, in addition, will differ from the Phase IIa trial in that intramuscular injections will be replaced by subcutaneous injections which would be better tolerated in the target patient population and, according to a recent clinical study in healthy volunteers, are as effective as the intramuscular injections. The interim results of the Phase IIa trial were presented earlier in November by Dr Edward Sellers, Senior Medical Consultant to Wex, at the 18th Annual Meeting of the International Society for Biological Therapy of Cancer in Bethesda, Maryland. The trial was a multicenter, open label, dose escalation study to evaluate the safety and analgesic effect of Tectin(TM) in patients with a variety of cancer pains. All patients had severe or worse pain, caused by their cancer or as a consequence of cancer treatment, and had failed currently established analgesic strategies. All enrolled patients completed the trial. Most patients (68%) achieved a clinically meaningful analgesic response based on the primary endpoint of 33% or more reduction in pain intensity. No serious adverse events were reported.

Tectin(TM) for the management of non-cancer related pain.

Wex is also pleased to announce that following the filing of the Clinical Trial Application (CTA) on November 12, 2003, it has received an 'Acknowledgement of Receipt or Screening Acceptance Letter'for 'An Open-Label Study Protocol to Assess the Safety and Efficacy of Tectin(TM) for Patients with Severe, Intractable, Non-malignant Chronic Pain'from Health Canada. This means that the dossier has been accepted for review, and, barring complications, approval of this study is expected in 30 days.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

Donna Shum, Corporate Secretary

The news release contains forward-looking statements that involve known and unknown risks and uncertainties, including discussions of preliminary Phase IIa clinical trial results. Final results could be different depending upon the outcome of further studies, interpretations, and additional clinical data. Forward-looking statements are based on current expectations; we assume no obligation to update such information to reflect later developments.



CONTACT: TEL: (604) 683-8880 Gordon Stanley, Corp. Communications

TOLL FREE: 1-800-722-7549

FAX: (604) 683-8868

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Website: www.wextech.ca

WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.